Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 2 034 DKK 0.39%
Updated: May 17, 2024

Genmab A/S
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genmab A/S
Cost of Revenue Peer Comparison

Comparables:
ZEAL
ASND
B
BAVA
BIOPOR
SANION

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Cost of Revenue
-kr411m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Cost of Revenue
-kr19.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Cost of Revenue
-€47.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Cost of Revenue
-kr2.5B
CAGR 3-Years
-28%
CAGR 5-Years
-57%
CAGR 10-Years
-18%
Bioporto A/S
CSE:BIOPOR
Cost of Revenue
-kr10.8m
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Saniona AB
STO:SANION
Cost of Revenue
-kr52.7m
CAGR 3-Years
19%
CAGR 5-Years
9%
CAGR 10-Years
N/A

See Also

What is Genmab A/S's Cost of Revenue?
Cost of Revenue
-411m DKK

Based on the financial report for Mar 31, 2024, Genmab A/S's Cost of Revenue amounts to -411m DKK.